Clinical Study
Topical Osmoprotectant for the Management of Postrefractive Surgery-Induced Dry Eye Symptoms: A Randomised Controlled Double-Blind Trial
Table 1
Baseline demographical and ophthalmological examination data of patients randomised into FT and Op treatments.
| | FT () | Op () | value |
| Age (years) | 38.21 ± 11.52 | 33.00 ± 7.75 | 0.4425 | Gender (as female %) | 71.4% | 54.5% | 0.4108 | OSDI (score) | 14.48 ± 3.26 | 24.95 ± 5.99 | 0.1176 | Schirmer 1 (mm/5 min) | 21.22 ± 10.47 | 25.77 ± 10.85 | 0.0961 | TBUT (sec) | 8.18 ± 4.02 | 8.28 ± 3.89 | 0.9758 | Fluorescein (score) | 0.15 ± 0.36 | 0.32 ± 0.68 | 0.1644 | Lissamine (score) | 1.04 ± 0.61 | 0.82 ± 0.66 | 0.2342 | BSCVA (LogMar) | 0.002 ± 0.052 | 0.036 ± 0.072 | 0.109 | Osmolarity (mOsm/L) | 359.5 ± 9.52 | 383.3 ± 8.33 | 0.0781 | Spherical equivalent (D) | −4.02 ± 2.8 | −3.56 ± 1.7 | 0.5745 | Contact lens users (%) | 42.86% | 44.44% | 0.7219 | Contact lens use (years) | 9.2 ± 10.2 | 8.5 ± 4.2 | 0.6689 |
|
|
Values represent mean ± standard deviation. OSDI: ocular surface disease index; TBUT: tear film breakup time; BSCVA: best spectacle-corrected visual acuity.
|